Mesalazine Nordic (Mesalazine)

Mesalazine works locally in the gut by inhibiting cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also modulates cytokine release and blocks NF‑κB signaling, resulting in reduced recruitment of inflammatory cells and decreased mucosal inflammation.

The prescribed dose of Mesalazine Nordic is individualized by the treating physician based on disease severity, location, and patient response. Dosage adjustments are made according to clinical guidelines and patient tolerance, and patients should follow the prescriber’s instructions exactly.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians weigh potential benefits against possible risks, and the drug is generally used only if the expected therapeutic advantage justifies exposure. Breastfeeding mothers should discuss potential infant exposure with their healthcare provider.

To order Mesalazine Nordic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesalazine Nordic delivers the same active moiety as other 5‑ASA products such as sulfasalazine, but it lacks the sulfapyridine component that can cause additional side effects. This often results in a more favorable tolerability profile, especially regarding hypersensitivity reactions, while providing comparable anti‑inflammatory efficacy.

Mesalazine Nordic should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct light, and kept out of reach of children.

The medication is taken orally, usually with a glass of water. It may be swallowed whole or, if a tablet, divided according to the prescriber’s guidance. Doses are typically spaced throughout the day to maintain steady drug levels in the intestine.

Serious adverse events, although rare, include pancreatitis, severe liver injury, blood dyscrasias such as neutropenia or thrombocytopenia, and severe hypersensitivity reactions like anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained abdominal pain, jaundice, unusual bleeding, or skin eruptions.

Mesalazine Nordic is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and in those who have experienced serious adverse reactions to other 5‑ASA agents.